Ispire Technology Inc Dossier
|
SectorConsumer Staples IndustryTobacco Beta (adjusted)1.61 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.34Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $77.4M Shares Outstanding 57.3M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ispire Technology Inc. (ISPR) is a highly speculative microcap transitioning from a cannabis-heavy hardware model to high-margin ODM technology and proprietary regulated nicotine platforms. While the stock has suffered a severe decline since its IPO, the company's proprietary age-gating technology (via its joint venture IKE Tech) presents significant event-driven optionality. However, near-term fundamentals remain weak with declining revenues, compressed gross margins, and persistent cash burn. A 'Hold' rating is recommended to monitor FDA regulatory catalysts and the operational ramp of its new Malaysia manufacturing facility. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.50 Mean target$5.00 High · most bullish analyst$6.50 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario FDA approval is indefinitely delayed or rejected, and organic growth continues to contract. Persistent cash burn forces dilutive equity financing or expensive debt restructuring, depressing the stock price further toward historical lows. Base CaseCentral scenario The company successfully stabilizes its organic revenue decline through its strategic shift to high-quality nicotine customers and the commercialization of its Malaysia plant. FDA approval for its age-gating technology remains delayed but viable, keeping speculative interest alive. Operating cash flow improves slightly but remains negative. Bull CaseUpside scenario Successful ramp of the Malaysia manufacturing facility to capture a 25% tariff advantage, combined with rapid adoption of the newly launched vapor ODM platform and commercialization of proprietary age-gating and G-Mesh technologies, driving high-margin revenue growth and positive cash flow in late 2026. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |